Literature DB >> 3143212

Modification of the Bethesda assay for factor VIII or IX inhibitors to improve efficiency.

J J Gadarowski1, E E Czapek, J D Ontiveros, J L Pedraza.   

Abstract

A factor IX inhibitor was assayed by using a modification of the Bethesda assay for factor VIII inhibitors. The incubation time was shortened to 15 min. A screening method using the activated partial thromboplastin time was used after sample incubation to determine the correct dilution of the patient's plasma to assay for residual factor IX activity prior to determining the inhibitor titer, thereby significantly reducing the number of factor assays needed. This screening method was also shown to be applicable to assaying a factor VIII inhibitor.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 3143212     DOI: 10.1159/000205619

Source DB:  PubMed          Journal:  Acta Haematol        ISSN: 0001-5792            Impact factor:   2.195


  4 in total

1.  Platelet gene therapy by lentiviral gene delivery to hematopoietic stem cells restores hemostasis and induces humoral immune tolerance in FIX(null) mice.

Authors:  Yingyu Chen; Jocelyn A Schroeder; Erin L Kuether; Guowei Zhang; Qizhen Shi
Journal:  Mol Ther       Date:  2013-08-23       Impact factor: 11.454

2.  Factor IX ectopically expressed in platelets can be stored in alpha-granules and corrects the phenotype of hemophilia B mice.

Authors:  Guowei Zhang; Qizhen Shi; Scot A Fahs; Erin L Kuether; Christopher E Walsh; Robert R Montgomery
Journal:  Blood       Date:  2010-05-05       Impact factor: 22.113

3.  The important role of von Willebrand factor in platelet-derived FVIII gene therapy for murine hemophilia A in the presence of inhibitory antibodies.

Authors:  Q Shi; J A Schroeder; E L Kuether; R R Montgomery
Journal:  J Thromb Haemost       Date:  2015-06-11       Impact factor: 5.824

Review 4.  An Update on Laboratory Diagnostics in Haemophilia A and B.

Authors:  Jens Müller; Wolfgang Miesbach; Florian Prüller; Thomas Siegemund; Ute Scholz; Ulrich J Sachs
Journal:  Hamostaseologie       Date:  2022-02-01       Impact factor: 2.145

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.